About FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FBLG Key Statistics
| Current Price | $0.42 | Market Cap | $28 million |
|---|---|---|---|
| Daily Change | +11.58% | Volume | 1.3M |
| 52-Week High | $1.53 | 52-Week Low | $0.22 |
| Sector | Healthcare | Industry | Biotechnology |
FBLG Price Performance
FibroBiologics, Inc. stock has returned +10.53% over the past day, +50.00% over the past week, +68.00% over the past month, and +23.53% over the past three months. The stock trades between a 52-week low of $0.22 and a high of $1.53.